Vaxcyte, Inc.
PCVX
$54.03
$0.040.07%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -85.73% | -65.25% | -29.46% | -10.12% | -16.67% |
| Total Depreciation and Amortization | 46.58% | 56.89% | 41.67% | 59.53% | 61.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 71.36% | 78.04% | 114.61% | 107.61% | 270.16% |
| Change in Net Operating Assets | 241.13% | 93.71% | 195.96% | 213.92% | -4,376.50% |
| Cash from Operations | -67.46% | -44.84% | -15.34% | 1.57% | -12.63% |
| Capital Expenditure | 66.37% | 52.19% | 46.25% | 9.39% | -80.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 109.68% | 126.20% | 88.12% | -186.64% | -84.84% |
| Cash from Investing | 105.63% | 121.81% | 83.93% | -143.37% | -84.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -62.50% | -99.47% | -99.37% | 56.05% | 15.77% |
| Repurchase of Common Stock | 7.86% | 23.10% | 35.20% | -112.06% | -126.62% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -63.04% | -99.92% | -99.82% | 55.45% | 15.15% |
| Foreign Exchange rate Adjustments | 113.51% | 472.54% | 141.98% | -13.90% | -589.95% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 67.53% | -2,184.11% | -252.19% | -1,645.20% | -214.33% |